

Cornelia STUMPTNER, Peter M. Abuja¹, Melina, Hardt¹, Katrin Panzitt¹, Carla Divieto², Alison Devonshire³, Carole Foy³, Esmeralda Valiente⁴, and other GenomeMET consortium members

¹ Medical University of Graz, Austria; ² Istituto Nazionale di Ricerca Metrologica, Italy; ³ LGC Ltd., UK; ⁴ Physikalisch-technische Bundesanstalt, Germany

Introduction & problem

In Europe, cancer caused 1.26 million deaths in 2020 and the number is expected to increase in future. Genomic profiling diagnostic tools such as next generation sequencing are important in cancer treatment, particularly to develop personalised targeted therapy and to aid early diagnosis.

However, quality and comparability of genomic profiling from patient samples, including biobank samples, varies significantly with standards and metrological means being in their infancy. Good reference measurement procedures and materials are needed for quality assurance.

Aim

GenomeMET aims to **improve the accuracy and comparability of genomic profiling across the European Healthcare System.**

GenomeMET Project & partners (2023 – 2026)


European Partnership for Metrology programme (22HLT06)



- It focusses on **developing a robust metrological (measurement) infrastructure** to support method validation and quality control at the pre-analytical and analytical stages.
- It will also **develop reference measurement procedures and test novel reference materials** for measuring genomic biomarkers.

Project structure

WP1: Reference Measurement Systems to support Genomic profiling



WP5 Impact: Network of Excellence, novel metrology capability, RMS, Standards development, best practice guidance, training

WP6: Management and coordination